Inhibitors of topoisomerase II: structure-activity relationships and mechanism of action of podophyllin congeners.

[1]  D. Sullivan,et al.  Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. , 1987, Cancer research.

[2]  K. Kohn,et al.  Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. , 1987, Cancer research.

[3]  S. Crooke,et al.  Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. , 1987, Cancer research.

[4]  M. Moore,et al.  Mutagenicity and clastogenicity of teniposide (VM-26) in L5178Y/TK +/- -3.7.2C mouse lymphoma cells. , 1987, Mutation research.

[5]  W. T. Beck,et al.  Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). , 1987, Cancer research.

[6]  Long Bh.  Structure-activity relationships of podophyllin congeners that inhibit topoisomerase II. , 1987 .

[7]  W. Ross,et al.  DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. , 1987, Pharmacology & therapeutics.

[8]  D. Sullivan,et al.  Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase. , 1987, NCI monographs : a publication of the National Cancer Institute.

[9]  R. Hertzberg,et al.  Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells. , 1987, NCI monographs : a publication of the National Cancer Institute.

[10]  K. Kohn,et al.  Topoisomerase alterations associated with drug resistance in a line of Chinese hamster cells. , 1987, NCI monographs : a publication of the National Cancer Institute.

[11]  W. Earnshaw,et al.  Topoisomerase II: A specific marker for cell proliferation , 1986, The Journal of cell biology.

[12]  M. Brattain,et al.  DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. , 1986, Cancer research.

[13]  E. Estey,et al.  Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites. , 1986, International journal of radiation oncology, biology, physics.

[14]  Y. Pommier,et al.  Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. , 1986, Cancer research.

[15]  G. Goldenberg,et al.  Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. , 1986, Cancer research.

[16]  D. Sullivan,et al.  Proliferation dependence of topoisomerase II mediated drug action. , 1986, Biochemistry.

[17]  W. Ross,et al.  Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. , 1986, Cancer research.

[18]  P. Cuatrecasas,et al.  Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Kohn,et al.  Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. , 1986, Cancer research.

[20]  H. Ikeda.  Bacteriophage T4 DNA topoisomerase mediates illegitimate recombination in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Ikeda.  Illegitimate recombination: role of type II DNA topoisomerase. , 1986, Advances in biophysics.

[22]  W. Ross.  DNA topoisomerases as targets for cancer therapy. , 1985, Biochemical pharmacology.

[23]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[24]  D. Osoba,et al.  VP-16 and cisplatin as first-line therapy for small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Y. Pommier,et al.  Correlations between intercalator-induced DNA strand breaks and sister chromatid exchanges, mutations, and cytotoxicity in Chinese hamster cells. , 1985, Cancer research.

[26]  M. Brattain,et al.  Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. , 1985, Cancer research.

[27]  N. Osheroff,et al.  In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Botstein,et al.  DNA topoisomerase II is required at the time of mitosis in yeast , 1985, Cell.

[29]  N. Osheroff,et al.  Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Earnshaw,et al.  Localization of topoisomerase II in mitotic chromosomes , 1985, The Journal of cell biology.

[31]  W. Earnshaw,et al.  Topoisomerase II is a structural component of mitotic chromosome scaffolds , 1985, The Journal of cell biology.

[32]  A. Pernet,et al.  Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[33]  L. Liu,et al.  Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. , 1984, Cancer research.

[34]  H. Martinson,et al.  Torsional stress promotes the DNAase I sensitivity of active genes , 1984, Cell.

[35]  J. Willson,et al.  Mitomycin C resistance in a human colon carcinoma cell line associated with cell surface protein alterations. , 1984, Cancer Research.

[36]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[37]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[38]  W. Ross,et al.  Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. , 1984, Biochimica et biophysica acta.

[39]  T. Uemura,et al.  Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. , 1984, The EMBO journal.

[40]  A. Minocha,et al.  Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. , 1984, Biochemical and biophysical research communications.

[41]  K. Kohn,et al.  Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. , 1984, Biochemistry.

[42]  R. Schimke.  Gene amplification in cultured animal cells , 1984, Cell.

[43]  Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells. , 1984, Cancer research.

[44]  P. Borst.  Cancer chemotherapy: DNA amplification and multidrug resistance , 1984, Nature.

[45]  A. Worcel,et al.  Chromatin assembly in Xenopus oocytes: In vitro studies , 1984, Cell.

[46]  R. Sternglanz,et al.  DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Brattain,et al.  Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. , 1984, Biochemistry.

[48]  L. Liu,et al.  Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Milbrandt,et al.  DNA sequence amplification in mammalian cells. , 1984, International review of cytology.

[50]  L. Liu,et al.  Cleavage of DNA by mammalian DNA topoisomerase II. , 1983, The Journal of biological chemistry.

[51]  R. Ralph,et al.  Evidence that mAMSA induces topoisomerase action , 1983, FEBS letters.

[52]  R. Gupta,et al.  Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. , 1983, Cancer research.

[53]  R. Gupta,et al.  Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells. , 1983, Environmental mutagenesis.

[54]  A. Wozniak,et al.  DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. , 1983, Cancer research.

[55]  S. Crooke,et al.  In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). , 1982, Cancer research.

[56]  L. Einhorn,et al.  Etoposide salvage therapy for refractory germ cell tumors: an update. , 1982, Cancer treatment reviews.

[57]  K. Aoki,et al.  Illegitimate recombination mediated in vitro by DNA gyrase of Escherichia coli: structure of recombinant DNA molecules. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[58]  K. Kohn,et al.  Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. , 1981, Biochemistry.

[59]  D. Brutlag,et al.  ATP-dependent DNA topoisomerase from D. melanogaster reversibly catenates duplex DNA rings , 1980, Cell.

[60]  N. Cozzarelli,et al.  Formation and resolution of DNA catenanes by DNA gyrase , 1980, Cell.

[61]  K. Kohn,et al.  Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. , 1979, Biochimica et biophysica acta.

[62]  F. Schabel,et al.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. , 1979, Cancer treatment reports.

[63]  Kelleher Jk.  Correlation of tubulin-binding and antitumor activities of podophyllotoxin analogs. , 1978 .

[64]  K W Kohn,et al.  DNA-protein cross-linking and DNA interstrand cross-linking by haloethylnitrosoureas in L1210 cells. , 1978, Cancer research.

[65]  J. Loike,et al.  Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. , 1978, Cancer research.

[66]  J. Kelleher.  Tubulin binding affinities of podophyllotoxin and colchicine analogues. , 1977, Molecular pharmacology.

[67]  J. Loike,et al.  Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. , 1976, Biochemistry.

[68]  V. Vaitkevicius,et al.  Phase II study of profiromycin vs mitomycin-C utilizing acute intermittent schedules. , 1976, Medical and pediatric oncology.

[69]  H. Stähelin,et al.  Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. , 1971, Journal of medicinal chemistry.

[70]  H. Savel.  The metaphase-arresting plant alkaloids and cancer chemotherapy. , 1966, Progress in experimental tumor research.